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Abstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and 
decreasing smoking prevalence is a public health priority. Patients achieve the greatest success 
when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline 
is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of 
tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse 
treatment-related side effects may decrease medication adherence and patient satisfaction with 
varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in 
patients who experience intolerable side effects, increasing the dose in partial responders, and 
providing long-term maintenance therapy for relapse prevention.
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Introduction
Despite the profound adverse health consequences of cigarette smoking, 46 million 
(20.6%) US adults continue to smoke every day or some days.1 On average, cigarette 
smokers will lose between 13 and 15 years of life as a direct consequence of smoking.2 
Over one-half of all lifetime smokers will die from smoking-related illness,3 and one 
out of every five deaths annually in the US is attributable to smoking.4,5 Direct health 
care costs related to illnesses caused by tobacco have been estimated at $96 billion 
per year.6
Smoking-related deaths are preventable, and stopping smoking has an immedi-
ate and dramatic impact on health and well being. Smoking abstinence reduces the 
risk of myocardial infarction and cardiovascular death. After one year of smoking 
abstinence, the excess risk (versus never smokers) of coronary heart disease mortality 
declines by one half.7 Risk of cardiovascular death among coronary heart disease 
patients who quit smoking is about half that of coronary heart disease patients who 
continue smoking.7,8 Fifteen years after quitting, the risk of coronary heart disease 
in former smokers is comparable with that of never smokers.7 After 5–15 years of 
smoking abstinence, the risk of stroke in a former smoker falls to that of a never 
smoker.7
Among patients with chronic obstructive pulmonary disease, stopping smoking 
decreases the rate of decline in lung function, chronic obstructive pulmonary disease-
related mortality, and all-cause mortality.9 Ten years after quitting, the risk of lung 
cancer in former smokers is 50%–70% less than that of continuing smokers.7Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Comprehensive tobacco 
dependence treatment
In 2000, an estimated 70% of US smokers had a desire to quit, 
and 40% made a quit attempt in the previous year.10 Smokers 
who seek and receive treatment in the form of behavioral and/
or pharmacologic therapy are more successful at quitting than 
those who do not seek help, yet only 20% of smokers who 
make a quit attempt will actually seek help.11 Most smokers 
who make unaided quit attempts relapse within eight days 
of quitting, and #5% of unaided quitters will achieve six-
month prolonged smoking abstinence.12 Clinicians should 
offer behavioral therapy and pharmacotherapy to all smokers 
who express a desire to quit.13
Behavioral interventions
Behavioral strategies (eg, intratreatment social support, 
practical counseling) are effective for increasing smoking 
abstinence rates.13 While even brief (,3 minutes per session) 
counseling is effective for promoting smoking abstinence, 
more intensive behavioral interventions are proportionally 
more effective. A meta-analysis observed the impact of 
behavioral counseling intensity on smoking abstinence to 
be dose-dependent, with high-intensity (ie, .10 minutes per 
session) counseling yielding higher smoking abstinence rates 
than low-intensity (ie, ,3 minutes per session) counseling 
(odds ratios [OR] 2.3, 95% confidence intervals [CI]: 2.0–2.7 
and OR 1.3, 95% CI: 1.01–1.6, for high-intensity and 
low-intensity counseling compared with no intervention, 
respectively).13 Behavioral counseling represents an integral 
component of comprehensive tobacco dependence treatment 
and is increasingly provided by nonphysician health care 
professionals trained as tobacco treatment specialists.
Pharmacotherapy
Seven “first-line” pharmacotherapies for tobacco dependence 
are currently available in the US, ie, sustained-release bupro-
pion, varenicline, and five forms of nicotine replacement 
therapy (ie, patch, gum, lozenge, inhaler, nasal spray).14 Two 
“second-line” treatments, clonidine and nortriptyline, are avail-
able, but have not received an indication for treating smokers 
by the US Food and Drug Administration (FDA).13 The present 
review will focus on treatment with varenicline.
Varenicline
Mechanism of action
The mechanism by which varenicline assists smokers in 
achieving smoking abstinence must be understood within the 
context of the role that nicotine plays in fostering tobacco 
dependence. Nicotine is the chemical in cigarette smoke 
leading to addiction.15 Upon inhaling cigarette smoke, nico-
tine is quickly absorbed into the bloodstream and readily 
penetrates the blood–brain barrier. Nicotine subsequently 
acts on neuronal nicotinic acetylcholine receptors within the 
ventral tegmental area of the brain, causing dopamine release 
in the nucleus accumbens which reinforces nicotine-seeking 
behavior.16 Reward through the dopaminergic system is a 
common thread among many drugs of addiction.17
Nicotine is a promiscuous ligand, binding to many nico-
tinic acetylcholine receptor subtypes found in the central 
nervous system and peripheral nervous system.16,18 Human 
neural nicotinic acetylcholine receptors are pentameric ion 
channels structurally composed of 11 subunits (α2–α7, α9, 
α10, β2–β4). The predominant neuronal nicotinic acetylcholine 
receptor subtypes in the central nervous system are the α4β2 
and α7 varieties.19 Of these, the former is most prevalent in the 
central nervous system, accounting for approximately 90% 
of central nervous system neuronal nicotinic acetylcholine 
receptors.19 This high prevalence and the high nicotine affinity 
of α4β2 neuronal nicotinic acetylcholine receptors for nicotine 
suggest that the α4β2 neuronal nicotinic acetylcholine recep-
tor is a key biomolecular target for the perpetuation of and 
treatment of nicotine addiction.20
Cytisine, an α4β2 neuronal nicotinic acetylcholine receptor 
partial agonist, has been used for over 50 years for smok-
ing cessation in Eastern Europe.21,22 During World War II, 
smokers used leaves from Cytisus laburnum, a cytisine-
containing plant, in place of tobacco.22 Although studies on 
cytisine appeared mildly promising, and a meta-analysis22 
concluded that it may be an effective pharmacotherapeutic 
aid for smoking cessation, several of the studies included 
in the meta-analysis had methodologic limitations. Conse-
quently, the drug’s efficacy remained in doubt and appeared 
to be limited by inadequate absorption and/or central nervous 
system penetration.23–25 The cytisine molecule was used as the 
structural basis for the ligand-based drug design of varenicline 
which could pass freely into the central nervous system.25
Varenicline possesses a receptor-dependent mode of 
action, acting as a low-efficacy partial agonist to the α4β2, 
α3β2 α3β4 and α6/α3β2β3 chimeric neuronal nicotinic acetyl-
choline receptor and a high-efficacy full agonist to the α7 
neuronal nicotinic acetylcholine receptor. The functional 
potency of varenicline is 8–24 times greater at the α4β2 
compared with the α7 and α3β4.26 The equilibrium binding 
affinity of α4β2 compared with α7 and α3β4 for varenicline 
has been reported to be two orders of magnitude more 
specific than the functional potency,25 perhaps reflecting Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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affinity for the receptor in the desensitized state.26 As a 
pharmacologic agent for tobacco dependence, varenicline’s 
partial agonism of the α4β2 is thought to promote smoking 
abstinence through stimulation of dopaminergic neurons 
and consequent amelioration of tobacco cravings and nico-
tine withdrawal.25 Partial antagonism at the α4β2 neuronal 
nicotinic acetylcholine receptor inhibits binding of nicotine, 
leading to diminished reward from smoking a cigarette.25 
Pharmacologic studies in rats have demonstrated that the 
relative agonist efficacy of varenicline is 40%–60% (relative 
to nicotine) and the relative nicotine antagonist efficacy is   
40%–55%.25
Varenicline has been observed to dampen the desire to 
smoke. Compared with placebo, craving is significantly lower 
for participants who receive varenicline (versus placebo, 
P , 0.001).27,28 Consistent with the proposed partial antago-
nist mechanism for varenicline, smoking satisfaction, and 
psychologic reward are also significantly decreased in smok-
ers taking varenicline (versus placebo, P , 0.001).27,28
Dosing
Varenicline treatment is initiated one week prior to the 
patient’s target quit date. Dosing begins at 0.5 mg once daily 
and increases to 0.5 mg twice daily on day 4. On the target 
quit date (day 8), the dose is increased to 1 mg twice daily 
and maintained for 12 weeks.
Clinical evidence for efficacy  
of varenicline
Two large, identically designed, multicenter, double-blind, 
Phase III, randomized, controlled clinical trials provided 
convincing evidence of the efficacy of varenicline for the 
treatment of tobacco dependence.27,28 One study27 observed 
44% continuous smoking abstinence during the last four 
weeks of treatment (weeks 9–12) for subjects taking 1 mg 
varenicline twice daily compared with 18% for placebo-
treated subjects (OR 3.85, 95% CI: 2.70–5.50) and 30% for 
sustained-release bupropion-treated (150 mg twice daily) 
subjects (OR 1.93, 95% CI: 1.40–2.68).27 At 52 weeks after 
randomization, varenicline significantly increased prolonged 
abstinence rates compared with placebo (21.9% versus 8.4%, 
OR 3.09, 95% CI: 1.95–4.91) and had marginal benefit 
compared with sustained-release bupropion (21.9% versus 
16.1%, OR 1.46, 95% CI: 0.99–2.17). Findings from the 
second Phase III trial28 were nearly identical, except that 
varenicline increased prolonged smoking abstinence rates 
significantly compared with sustained-release bupropion at 
52 weeks (OR 1.77, 95% CI: 1.19–2.63).
Varenicline also appears to be more efficacious than 
nicotine replacement therapy. In an open-label study,29 par-
ticipants randomly received varenicline (1 mg twice daily) 
for 12 weeks or transdermal nicotine replacement therapy 
(21 mg/day, tapered to 7 mg/day) for 10 weeks. Prolonged 
smoking abstinence for the last four weeks of treatment 
was higher for varenicline-treated participants than patients 
receiving the nicotine patch (56% versus 43.2%, OR 1.70, 
95% CI: 1.26–2.28). At one year, a trend was observed toward 
increased efficacy with varenicline compared with the nico-
tine patch for prolonged smoking abstinence (26% versus 
20% prolonged abstinence, OR 1.40, 95% CI: 0.99–1.99).
A recent meta-analysis30 compiled the data from six 
clinical trials including 2583 participants receiving either 
varenicline or placebo. The analysis yielded a risk ratio 
(RR) for continuous smoking abstinence over weeks 9–24 
of 2.34 (95% CI: 1.99–2.75) favoring varenicline 1.0 mg 
twice daily. The meta-analysis also reported on three studies 
that compared varenicline with sustained-release bupropion. 
Varenicline was observed to be superior to bupropion (RR 
1.52, 95% CI: 1.22–1.88) for continuous abstinence at   
week 52.
Longer durations of therapy with varenicline have been 
shown to be more effective than shorter durations. In a 
study evaluating longer duration of therapy,31 participants 
achieving smoking abstinence at the end of treatment after 
12 weeks with open-label varenicline were randomized to 
either varenicline 1 mg twice daily or placebo for an addi-
tional 12 weeks. At the end of the second treatment phase 
(week 24 of the study), 71% of participants receiving active 
treatment remained abstinent from smoking compared with 
50% of participants receiving placebo (OR 2.48, 95% CI: 
1.95–3.16). After 52 weeks of follow-up, subjects receiving 
varenicline had significantly higher smoking abstinence 
rates compared with those receiving placebo (44% versus 
37% continuous abstinence over weeks 13–52, OR 1.34, 
95% CI: 1.06–1.69).
A secondary analysis of the data from this study sug-
gests that, when used for relapse prevention, the additional 
12-week course of varenicline is more effective in smokers 
who initially have difficulty achieving smoking abstinence.32 
When treatment effect of maintenance therapy was analyzed 
separately for early quitters (ie, those who quit at week 1) 
and late quitters (ie, those who quit after the first week of 
treatment), the additional 12 weeks of maintenance therapy 
was more helpful for relapse prevention in late quitters (OR 
1.7, 95% CI: 1.2–2.4) than in early quitters (OR 1.1, 95% 
CI: 0.8–1.5).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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The safety and efficacy of long-term treatment (.six 
months) with varenicline has been demonstrated. In a study 
on 377 adult smokers, participants were randomized to 
varenicline (1 mg twice daily) or placebo for 52 weeks. The 
drug was well tolerated. Most adverse effects were experi-
enced during the first four weeks of the treatment phase and 
adverse event incidence decreased over time. The seven-day 
point prevalence smoking abstinence rate at week 52 was 
37% for varenicline-treated subjects compared with 8% for 
the placebo group.33
Varenicline in combination 
pharmacotherapy
None of the available first-line medications for treating tobacco 
dependence have labeled indications for use in combination 
with another. However, multiple trials of combination therapy 
have been published, and show improved smoking abstinence 
rates compared with monotherapy.34 Combination therapy 
with varenicline has only been studied in small clinical trials 
to date. An open-label pilot study35 in smokers investigated 
12 weeks of therapy with varenicline (standard treatment 
regimen) coadministered with sustained-release bupropion 
(150 mg twice daily after a three-day dose escalation). The 
seven-day point prevalence smoking abstinence rate among 
38 enrolled smokers was 71% (95% CI: 54–85) at the end of 
treatment. At six months, combination therapy continued to 
appear more effective than monotherapy, although an appro-
priately powered, double-blind, randomized, controlled trial 
is necessary to confirm these findings.
Combination therapy with varenicline and nicotine 
replacement therapy has also been evaluated. Heavier smok-
ers might benefit from this combination because varenicline 
might not fully saturate nicotinic receptors during dose esca-
lation. Incompletely saturated receptors may lead to partial 
attenuation of nicotine cravings. If supplemental nicotine 
replacement therapy can lead to more complete receptor 
saturation, then urges to smoke could be more completely 
attenuated. This possible effect was evaluated in an eight-
day residential treatment program.36 The first study group 
(n = 135) completed the residential treatment program prior to 
the release of varenicline and received “usual care” consisting 
of nicotine patch therapy and/or sustained-release bupropion. 
Short-acting forms of nicotine replacement therapy were 
used ad libitum for treatment of acute nicotine withdrawal 
symptoms. The second group (n = 104) completed the 
residential treatment program after FDA approval of vareni-
cline and received combination therapy with varenicline 
and nicotine replacement therapy. Nicotine patch therapy 
was the predominant form of nicotine replacement therapy 
used, and it was often supplemented with short-acting forms 
of nicotine replacement therapy. Nearly three-quarters of 
patients used more than one form of nicotine replacement 
therapy. No significant differences were observed in 30-day 
point prevalence smoking abstinence rates between the two 
groups at six months. Importantly, no increase in reported 
side effects in patients receiving the combination treatment 
was observed. Major limitations to this study were the small 
sample size and uncontrolled study design.
Medication adherence
Direct associations exist between adherence to medication 
therapy and treatment outcomes. One-fifth of smokers who 
receive medication for the treatment of tobacco dependence 
fail to fill their prescriptions.37 When patients start medica-
tion, medication adherence becomes an issue. In a post hoc 
analysis38 of data from the first two Phase III clinical trials 
on varenicline for treating tobacco dependence,27,28 a positive 
correlation between adherence to treatment regimen (defined 
as taking $1 dose of study medication for $80% of days of 
the treatment period) and smoking abstinence was observed 
for all three study arms (varenicline, sustained-release 
bupropion, and placebo). This suggests a “healthy adherer 
effect” with individuals adhering to a prescribed treatment 
having more favorable outcomes independent of treatment 
assignment. Factors found to be significant predictors of 
smoking abstinence included older age, fewer number 
of cigarettes smoked per day, and achievement of early 
smoking abstinence. Achievement of smoking abstinence 
in the first two weeks was the most significant predictor of 
adherence.
To maximize drug efficacy, patients need to adhere to dos-
ing guidelines. With this in mind, prescribers should consider 
factors that influence patient adherence, such as medication 
cost, dosing frequency, and the adverse effect profile. They 
should also educate patients about the rationale for treatment 
and possible side effects, and reinforce the importance of 
treatment adherence.38
Medication cost
Medication cost appears to influence both patient utiliza-
tion of smoking cessation interventions and abstinence. 
One study randomized 1204 smokers to receive either a 
self-help video and pamphlet only or to the self-help video 
and pamphlet in addition to full insurance coverage for over-
the-counter nicotine replacement therapy combined with 
group behavioral therapy at no cost. Participants were not Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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obligated to make a quit attempt during the study. Providing 
full coverage of behavioral therapy and pharmacotherapy 
with no participant cost-sharing increased the rate of quit 
attempts (adjusted OR 1.4, 95% CI: 1.1–1.8) and nicotine 
replacement therapy use (adjusted OR 2.3, 95% CI: 1.6–3.2). 
One-year smoking abstinence rates were also higher in the 
group that received free medication and behavioral therapy 
(18% versus 13% self-reported seven-day point prevalence 
smoking abstinence; adjusted OR 1.6, 95% CI: 1.1–2.4).39 
Another study observed that higher rates of tobacco treat-
ment service utilization occurred among insured patients 
with full coverage compared with those with partial cover-
age (ie, cost-sharing).40 Notably, the full coverage group 
demonstrated lower smoking abstinence rates. However, 
the higher utilization among the fully-insured offset the 
lower abstinence rates, such that the overall prevalence of 
smoking was greater with full coverage than with the cost-
sharing plans. A study of 7513 pregnant Medicaid enrollees 
who were smokers prior to pregnancy demonstrated that 
Medicaid coverage for treating tobacco dependence was 
directly associated with greater smoking abstinence rates. 
Female smokers in states providing extensive coverage (ie, 
pharmacotherapy and behavioral counseling) had a 51% 
quit rate during pregnancy compared with a 39% quit rate 
for women in states that provided no Medicaid coverage 
for tobacco dependence treatment (adjusted OR 1.58, 95% 
CI: 1.00–2.49). Women who lived in states that provided only 
partial Medicaid coverage (ie, pharmacotherapy or counsel-
ing only) had intermediate smoking abstinence rates (43%, 
adjusted OR versus no coverage 1.18, 95% CI: 1.03–1.34).41 
These studies indicate that comprehensive insurance coverage 
for tobacco dependence treatment can have a positive effect 
on smoking abstinence outcomes.
No generic formulation of varenicline is available, so the 
drug must be purchased as Chantix® in the US or Champix® 
elsewhere. Chantix costs roughly US $4–5 per day for nor-
mal dosing, although this may vary regionally.13 Although 
patients often only consider the immediate and direct cost of 
medication, cost-benefit analyses have demonstrated the long-
term cost effectiveness of varenicline. A cost-utility analysis 
factoring in direct medical costs of treating smoking-related 
disease estimated that varenicline is the most cost-effective 
pharmacotherapy for treating tobacco dependence in terms 
of cost per quality-adjusted life year. When a US population 
is used in the model, varenicline treatment for smokers costs 
US $1884 per quality-adjusted life year, compared with 
$1902, $1912, and $1922 for bupropion, nicotine replace-
ment therapy, and unaided attempts to quit, respectively.42 
The finding of superior cost-effectiveness for varenicline 
versus other treatments for smokers has been replicated in 
other simulations using different populations.43–46 Doubling 
the treatment duration with varenicline was more costly but 
still cost-effective. Simulations estimated an incremental 
cost of $972 per quality-adjusted life year for a 24-week 
treatment when compared with 12 weeks.47 However, cost 
effectiveness does not translate into the calculation of cost 
for the individual patient. Clinicians need to be sensitive 
to cost, and explore with their patient ways to mitigate the 
financial burden posed by filling prescriptions and by mini-
mizing side effects.
Adverse effects of varenicline
The most commonly reported adverse events experienced by 
subjects on varenicline in clinical trials were nausea (28.1% 
versus 8.4% placebo), headache (15.5% versus 12.2%), 
insomnia (14.0% versus 12.8%), and abnormal dreams 
(10.3% versus 5.5%).27 A recent meta-analysis compiled the 
available data on adverse events in these clinical trials with 
varenicline. Compared with placebo, varenicline increases 
the risk for nausea (RR 3.25, 95% CI: 2.73–3.86), insomnia 
(RR 1.45, 95% CI: 1.21–1.75), and abnormal dreams (RR 
2.79, 95% CI: 2.09–3.72).30 In clinical trials, only 8.6% of 
study subjects who received varenicline (versus 9.0% pla-
cebo) discontinued treatment due to adverse effects.27
Since 2007, reports of neuropsychiatric adverse events 
experienced by patients taking varenicline have evoked sig-
nificant concern about the drug’s safety. In November 2007, 
the FDA disclosed post-marketing surveillance data indicating 
reports of suicidal ideation, mood and behavior disturbances, 
and depression emerging in patients shortly after commencing 
treatment with varenicline.48 In 2008, the FDA mandated a 
revision to the Chantix product insert to include a warning 
that severe neuropsychiatric symptoms have been experienced 
by patients taking the drug. Health care providers are advised 
to monitor patients who take varenicline closely and patients 
are urged to seek a medical professional if neuropsychiatric 
adverse events are experienced.49 In 2009, the FDA required 
that varenicline and bupropion both carry on their packaging 
“boxed” warnings, the strongest warning given by the FDA, 
about a possible link between the drug and the onset of neu-
ropsychiatric adverse effects.50
The recent case reports on adverse events with vareni-
cline are challenging to interpret because the reports are 
anecdotal and the described events have also been observed 
among patients attempting to stop smoking. The Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV-TR) Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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associates nicotine withdrawal with a plethora of adverse 
neuropsychiatric symptoms, including dysphoric or depressed 
mood, insomnia, irritability, frustration, anger, and anxiety.51 
In an attempt to conduct a more rigorous assessment of the 
safety profile of varenicline, a pooled analysis of psychiatric 
adverse events from 10 randomized, controlled trials treating 
a total of 3091 participants with varenicline was performed. 
The analysis reported no significant increase in overall psy-
chiatric disorders due to varenicline other than sleep disorders 
and disturbances (RR 1.70, 95% CI: 1.50–1.93).52
Forthcoming clinical trials required by the FDA53 should 
paint a clearer picture of the incidence of neuropsychiatric 
adverse effects experienced by individuals, including smok-
ers diagnosed with psychiatric disorders, using various treat-
ment strategies for tobacco dependence.
Recommendations for efficacy  
and adherence with varenicline
The US Surgeon General has concluded that “the health 
benefits of smoking cessation far exceed any risks from … 
adverse psychological effects that may follow quitting”.7 
Presently available data have not proven that varenicline 
causes significant neuropsychiatric adverse events. However, 
until more is known about potential neuropsychiatric adverse 
effects, clinicians should closely monitor patients who are 
taking varenicline. In the absence of a proven causal link 
between varenicline and a serious risk of neuropsychiatric 
adverse effects, the immense health benefits of smoking ces-
sation warrant its continued use as a pharmacologic aid for 
treating tobacco dependence. Clinical monitoring is needed 
to ensure patient progress and safety.
The efficacy of varenicline is dependent upon adherence 
to medication therapy. Clinicians should choose appropri-
ate treatments tailored to patient preferences and adjust 
the dosing regimen as needed to maximize adherence and 
efficacy and minimize patient discomfort. Communication is 
fundamental and clinicians should work to establish an open 
dialog with patients to discuss the importance of medication 
adherence, as well as strategies for mitigating side effects.
Decreasing side effects
Nausea is the most common side effect associated with 
varenicline.27,28 If patients experience nausea which prompts 
them to consider therapy discontinuation, we advocate edu-
cating them on the importance of taking varenicline with 
food and an 8 oz glass of water. If these interventions do not 
improve symptoms, the daily dose of varenicline can be 
reduced because nausea appears to be a dose-dependent 
adverse effect.54 Varenicline remains more efficacious than 
placebo when the daily dose is halved (to 0.5 mg twice daily) 
and taken for 12 weeks. Week 9–52 abstinence rates were 
18.5% for subjects who received 0.5 mg varenicline twice 
daily compared with 3.9% for subjects who received placebo 
(P , 0.001).55
The half-life of varenicline is approximately 17 hours 
supporting once-a-day dosing.56 However, splitting the dose 
into two doses per day is believed to reduce the incidence of 
nausea and vomiting.54 Dividing the daily dose further into 
more than two administrations per day may be an effective 
strategy for mitigating these symptoms in patients already 
taking the drug twice daily.
Increasing efficacy in patients who have 
difficulty remaining abstinent
The treatment of tobacco dependence is characterized by 
relapses and remissions, and patients often make many quit 
attempts before achieving long-term smoking abstinence.13 As 
previously discussed, smokers who are unable to quit smok-
ing on their target quit date, but who eventually quit during 
the treatment period with varenicline appear to benefit from 
an additional 12 weeks of therapy.32 We recommend mainte-
nance therapy as an effective strategy for relapse prevention 
in smokers who are initially unsuccessful at quitting.
Preliminary evidence suggests that partial responders 
to varenicline may benefit from an increased dose. A small 
case-control study (n = 56) observed that increasing the dose 
of varenicline from 2 mg per day to 3 mg per day at week 6 in 
highly nicotine-dependent partial responders to varenicline 
(ie, smokers who reduce cigarette consumption but fail to quit 
at week 6 while on drug) may be effective. Compared with 
control cases who failed to achieve early abstinence while 
on 12 weeks of varenicline at 2 mg per day, dose-escalated 
patients had more favorable smoking abstinence outcomes 
(seven-day point prevalence) at week 12 (35.7% versus 
14.3%, OR 3.33, 95% CI: 0.90–12.36).57 Although this dosing 
regimen is not approved by the FDA, and these findings have 
yet to be validated in a larger controlled clinical trial, highly-
dependent smokers may benefit from this approach.
Patient selection
Varenicline is an FDA pregnancy category C drug. Stud-
ies on rats and rabbits observed decreased fetal weight and 
decreased offspring fertility after administration of high 
doses of varenicline. The effects of varenicline on pregnant 
humans and their offspring have not been adequately inves-
tigated, nor is it known whether varenicline is excreted in the Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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milk of nursing mothers.58 For this reason, varenicline is not 
recommended for pregnant or nursing mothers unless the 
drug’s benefit justifies the potential risk posed to the fetus. 
Care should be taken in patients with severe renal dysfunction 
(creatinine clearance , 30 mL/min); decreasing the dose to 
0.5 mg/day is recommended for this patient population.13
Conclusion
Not every quit attempt made by a smoker will be successful, 
but combined behavioral therapy and pharmacotherapy sig-
nificantly improves the odds of achieving tobacco abstinence. 
Smokers taking varenicline have the most success quitting 
compared with those taking other first-line pharmacothera-
pies for treating tobacco dependence. Although barriers, 
such as unsuccessful quit attempts and adverse side effects, 
may decrease adherence and impair patient satisfaction with 
tobacco dependence treatment, clinicians should work with 
patients to adjust pharmacotherapy to suit the individual 
patient’s needs and help the smoker achieve long-term smok-
ing abstinence.
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